The Science Times Publishes Article About Jaguar Health's Focus On Developing Crofelemer For Two Rare Disease Indications
Portfolio Pulse from Happy Mohamed
Jaguar Health, Inc. (NASDAQ:JAGX) is focusing on developing its plant-based prescription drug, crofelemer, for two rare disease indications, short bowel syndrome (SBS) and microvillus inclusion disease (MVID). The company is supporting proof-of-concept studies in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2023 and in 2024. The FDA and the European Medicines Agency have granted Orphan Drug Designation for crofelemer for both MVID and SBS.
August 30, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's focus on developing crofelemer for two rare diseases could potentially open new revenue streams if the drug is approved and successfully commercialized.
The development of crofelemer for two rare diseases could potentially open new revenue streams for Jaguar Health if the drug is approved and successfully commercialized. The company's focus on these diseases indicates a strategic move to target niche markets, which could lead to significant revenues if successful.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100